Translational Neuroscience Optimization of GlyT1 Inhibitor

Trial Profile

Translational Neuroscience Optimization of GlyT1 Inhibitor

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs PF 3463275 (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Proof of concept; Therapeutic Use
  • Acronyms NCATS
  • Most Recent Events

    • 22 Jun 2017 Study design changed from parallel to crossover, treatments changed from 10, 20 mg & 40 mg dose to 40 mg & 60 mg dose (study arms changed from 4 to 3), patient inclusion changed to include patients with schizophrenia & Schizoaffective disorder and age group 21-65 years, planned patient number changed from 36 to 90. Primary outcome measure changed from receptor occupancy at 6 weeks to effect of PF-03463275 on cognitive measures at approximately 5 weeks.
    • 22 Jun 2017 Planned number of patients changed from 36 to 90.
    • 19 May 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top